ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Medicare"

  • Abstract Number: 0533 • ACR Convergence 2020

    Characterization of Older Male Patients with a Fragility Fracture

    Setareh A Williams1, Shanette G Daigle2, Richard Weiss1, Yamei Wang1, Tarun Arora2 and Jeffrey R Curtis3, 1Radius Health, Inc., Waltham, MA, Waltham, MA, 2University of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Osteoporosis is associated with significant burden in terms of adverse patient outcomes, mortality, and cost; and is particularly common in the older Medicare population.…
  • Abstract Number: 0609 • ACR Convergence 2020

    Impact of Depressive Symptoms, Anti-depression Treatment on Direct Medical Costs Among Medicare Beneficiaries with Knee Osteoarthritis (KOA)

    Shuang Song1, Jeffrey Katz2 and Elena Losina2, 1Brigham and Women's Hospital, Brighton, MA, 2Harvard Medical School / The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Depressive symptoms are prevalent among knee OA (KOA) patients and likely lead to additional medical costs. We sought to quantify the prevalence of depressive…
  • Abstract Number: 0612 • ACR Convergence 2020

    Differences in 30-Day Rehospitalization Risk and Predictors by Age Group Among Patients with Lupus in Medicare

    Maria Schletzbaum1, Yi Chen2, Ann Sheehy3, Farah Kaiksow3, Ryan Powell4, Andrea Gilmore-Bykovskyi5, Amy Kind6 and Christie Bartels7, 1University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Department of Medicine, Hospital Medicine Division, Madison, WI, 4University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division, Madison, WI, 5University of Wisconsin - Madison, School of Nursing, Madison, WI, 6University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Health Services and Care Research Program, Geriatrics Division, Madison, WI, 7University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

    Background/Purpose: Although our recent research demonstrates that young adult Medicare beneficiaries (age 18-35) with lupus (SLE) have higher risk of 30-day rehospitalization, predictors specific to…
  • Abstract Number: 1281 • ACR Convergence 2020

    Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus

    Christie Bartels1, Maria Schletzbaum2, Yi Chen3 and Amy Kind4, 1University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, 2University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, Madison, WI, 4University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Health Services and Care Research Program, Geriatrics Division, Madison, WI

    Background/Purpose: One in four Medicare hospitalizations with systemic lupus erythematosus (SLE) results in readmission within 30 days, with “injuries and poisonings” as the second most…
  • Abstract Number: 1422 • ACR Convergence 2020

    Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data

    Zachary Wallace1, Xiaoqing Fu2, John Stone3, Hyon Choi4 and Rochelle Walensky2, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Concord, MA, 4Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: ANCA-associated vasculitis (AAV) leads to complications that contribute to poor quality of life and survival.  Systemic vasculitis is associated with high healthcare utilization but…
  • Abstract Number: 1758 • ACR Convergence 2020

    Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data

    Robin Dore1, Jenya Antonova2, Lawrence Chang2, Suying Li3, Haifeng Guo3, Yuanyuan Ji3 and Mark Genovese4, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3Chronic Disease Research Group, Minneapolis, MN, 4Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…
  • Abstract Number: 0055 • ACR Convergence 2020

    Racial and Sex-based Disparities in Health Care Utilization: Eye Inflammation as a Paradigm

    Krati Chauhan1 and James Rosenbaum2, 1Southern Illinois University - School of Medicine, Springfield, IL, 2Oregon Health & Science University, Portland, OR

    Background/Purpose: Disparities in health care utilization based on sex, race, education, or income affect outcomes in rheumatologic care. We have used ocular inflammatory and infectious…
  • Abstract Number: 0181 • ACR Convergence 2020

    Methotrexate Use Does Not Increase the Prevalence of Hepatic Steatosis: A Real-World Retrospective Nested Case-Control Study

    Yunjung Choi1, Chang-Hun Lee1, Myeung-Su Lee2, Chang-Hoon Lee2, SoJeong Park3 and Wan-Hee Yoo4, 1Jeonbuk National University Hospital, Jeonju, Republic of Korea, 2Wonkwang University Hospital, Iksan, Republic of Korea, 3Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Romania, 4Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea

    Background/Purpose: We aimed to determine whether methotrexate (MTX) treatment in patients with rheumatoid arthritis (RA) leads to the development of nonalcoholic fatty liver (NAFL).Methods: Data…
  • Abstract Number: 258 • 2019 ACR/ARP Annual Meeting

    Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus

    Geyanne Lui1, Mangala Rajan 1, Lisa Kern 1, Laura Pinheiro 1, Monika Safford 1, Jeffrey Curtis 2 and Iris Navarro-Millan 1, 1Weill Cornell Medicine, New York, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Medicare beneficiaries who are disabled (coverage by the Social Security Disability Insurance (SSDI)) with rheumatoid arthritis (RA) and diabetes mellitus (DM) and under 65…
  • Abstract Number: 953 • 2019 ACR/ARP Annual Meeting

    Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data

    Robin Dore1, Lawrence Chang 2, Yuanyuan Ji 3, Suying Li 3, Jenya Antonova 2 and Mark Genovese 4, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3Chronic Disease Research Group, Minneapolis, MN, 4Stanford University, Stanford, CA

    Background/Purpose: In RA patients not meeting treat-to-target goals despite treatment with a biologic (b)DMARD, ACR guidelines1 recommend using other targeted immunomodulators (TIM): TNF-α inhibitor (TNFi),…
  • Abstract Number: 1426 • 2019 ACR/ARP Annual Meeting

    Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib

    James Harnett1, Timothy Smith 1, John Woolcott 2, David Gruben 3 and Christopher Murray 2, 1Pfizer Inc, New York, NY, 2Pfizer Inc, Collegeville, PA, 3Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. It was approved for RA by the US FDA in Nov 2012. TNFi…
  • Abstract Number: 2333 • 2019 ACR/ARP Annual Meeting

    Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance

    Iris Navarro-Millan1, Mangala Rajan 1, Geyanne Lui 1, Lisa Kern 1, Laura Pinheiro 1, Sebastian E. Sattui 2, Lisa Mandl 3, Fenglong Xie 4, Jeffrey Curtis 5 and Monika Safford 1, 1Weill Cornell Medicine, New York, 2Hospital for Special Surgery, New York, 3Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, 4University of Alabama at Birmingham, Birmingham, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Patients with RA have high risk for myocardial infarction (MI). A meta-analysis showed that the age and sex adjusted pooled relative risk of MI…
  • Abstract Number: 293 • 2018 ACR/ARHP Annual Meeting

    Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays

    Jeffrey R. Curtis1, Rui Chen1, Tarun Arora1, Shanette Daigle1, Robert Matthews1, Huifeng Yun1, Nicole Wright2, Ayesha Jaleel3, Elizabeth Delzell4 and Kenneth Saag5, 1University of Alabama at Birmingham, Birmingham, AL, 2Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmngham, AL, 4Retired - University of Alabama at Birmingham, Birmingham, AL, 5UAB, Birmingham, AL

    Background/Purpose: Safety concerns related to osteoporosis (OP) medication use and temporary or permanent cessation of bisphosphonate therapy (e.g. ‘drug holidays’) have generated appreciable attention in…
  • Abstract Number: 519 • 2018 ACR/ARHP Annual Meeting

    Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry

    Huifeng Yun1, Lang Chen1, Jason Roy2, Jeffrey D. Greenberg3 and Jeffrey R. Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Pennsylvania, Philadelphia, PA, 3Hopital Hautepierre, Strasbourg, France

    Background/Purpose: Higher disease activity might be associated with a higher risk of developing infections among patients with rheumatoid arthritis (RA). Since no randomized trial has…
  • Abstract Number: 885 • 2018 ACR/ARHP Annual Meeting

    Herpes Zoster in Tofacitinib Users with and without Concomitant Methotrexate and Glucocorticoids

    Jeffrey R. Curtis1, Fenglong Xie1, Sasha Bernatsky2, Shuo Yang1, Lang Chen1, Huifeng Yun1 and Kevin Winthrop3, 1University of Alabama at Birmingham, Birmingham, AL, 2Division of Rheumatology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3Oregon Health and Science University, Portland, OR

    Background/Purpose: An increased incidence of herpes zoster (HZ) has been observed with Janus kinase inhibitors such as tofacitinib (TOF). However, among TOF users, a potentially…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.